Prospects for primary prevention of cervical cancer in developing countries
Fuente:
Redalyc
Gespeichert in:
| 1. Verfasser: | |
|---|---|
| Format: | Artículo científico |
| Sprache: | en |
| Veröffentlicht: |
Instituto Nacional de Salud Pública
2003
|
| Schlagworte: | |
| Online-Zugang: | |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| _version_ | 1876446935340023808 |
|---|---|
| author | Gary Clifford |
| author_facet | Gary Clifford |
| contents | Prospects for primary prevention of cervical cancer in developing countries Gary Clifford Martyn Plummer Silvia Franceschi Salud projection vaccination cervix neoplasms randomized controlled trials The HPV types that cause cervical cancer are sexually transmitted,but there is little evidence that infection can be avoidedby behavioural changes, such as condom use. In contrast,prophylactic vaccines against HPV infection are likely to havehigh efficacy. In principle, the effectiveness of HPV vaccinationas a strategy for cervical cancer control can be measuredeither by monitoring secular trends in cervical cancer incidenceor by conducting randomized trials. The former approachis unlikely to provide convincing evidence of effectiveness,since cervical cancer rates are subject to strong seculartrends that are independent of intervention measures. Afew phase III trials of HPV prophylactic vaccines are nowbeing started. Such trials are very expensive studies involvingfrequent and complicated investigations. It is important,however, to start as soon as possible simpler trials designedto demonstrate the effectiveness of HPV vaccine in fieldconditions, i.e. in developing or intermediate countries whichsuffer the major burden of mortality from cervical cancer.Such trials may capture a difference in the most severe, andrarest, preinvasive cervical lesions (i.e., the real target ofany HPV vaccine) over a prolonged follow-up (20 years atleast). The design of such studies is briefly considered fortwo areas: Southern India and South Korea. This paper isavailable at: http://www.insp.mx/salud/index.html 2003 artículo científico 0036-3634 https://www.redalyc.org/articulo.oa?id=10609717 en http://www.redalyc.org/revista.oa?id=106 Salud Pública de México application/pdf Instituto Nacional de Salud Pública Salud Pública de México (México) Num.3 Vol.45 |
| format | Artículo científico |
| id | redalyc_10609717 |
| institution | Redalyc |
| language | en |
| publishDate | 2003 |
| publisher | Instituto Nacional de Salud Pública |
| spellingShingle | Prospects for primary prevention of cervical cancer in developing countries Gary Clifford Salud projection vaccination cervix neoplasms randomized controlled trials Prospects for primary prevention of cervical cancer in developing countries Gary Clifford Martyn Plummer Silvia Franceschi Salud projection vaccination cervix neoplasms randomized controlled trials The HPV types that cause cervical cancer are sexually transmitted,but there is little evidence that infection can be avoidedby behavioural changes, such as condom use. In contrast,prophylactic vaccines against HPV infection are likely to havehigh efficacy. In principle, the effectiveness of HPV vaccinationas a strategy for cervical cancer control can be measuredeither by monitoring secular trends in cervical cancer incidenceor by conducting randomized trials. The former approachis unlikely to provide convincing evidence of effectiveness,since cervical cancer rates are subject to strong seculartrends that are independent of intervention measures. Afew phase III trials of HPV prophylactic vaccines are nowbeing started. Such trials are very expensive studies involvingfrequent and complicated investigations. It is important,however, to start as soon as possible simpler trials designedto demonstrate the effectiveness of HPV vaccine in fieldconditions, i.e. in developing or intermediate countries whichsuffer the major burden of mortality from cervical cancer.Such trials may capture a difference in the most severe, andrarest, preinvasive cervical lesions (i.e., the real target ofany HPV vaccine) over a prolonged follow-up (20 years atleast). The design of such studies is briefly considered fortwo areas: Southern India and South Korea. This paper isavailable at: http://www.insp.mx/salud/index.html 2003 artículo científico 0036-3634 https://www.redalyc.org/articulo.oa?id=10609717 en http://www.redalyc.org/revista.oa?id=106 Salud Pública de México application/pdf Instituto Nacional de Salud Pública Salud Pública de México (México) Num.3 Vol.45 |
| title | Prospects for primary prevention of cervical cancer in developing countries |
| topic | Salud projection vaccination cervix neoplasms randomized controlled trials |
| url | https://www.redalyc.org/articulo.oa?id=10609717 |